New desulfured troglitazone derivatives: Improved synthesis and biological evaluation - Université de Lorraine Access content directly
Journal Articles European Journal of Medicinal Chemistry Year : 2020

New desulfured troglitazone derivatives: Improved synthesis and biological evaluation

Dorian Dupommier
Claire Muller
  • Function : Author
  • PersonId : 1039668
  • IdRef : 262394804
Corinne Comoy
Elia de Fays
  • Function : Author
  • PersonId : 1039669

Abstract

Breast cancer is a major medical threat which cannot be sufficiently addressed by current therapies because of spontaneous or acquired treatment resistance. Besides, triple-negative breast cancer (TNBC) tumors do not respond to targeted therapies, thus new therapeutic strategies are needed. In this context, we designed and prepared new desulfured troglitazone (TGZ)-derived molecules and evaluated them in vitro for their anti-proliferative activity, with a special focus on triple-negative breast cancer cell lines. Optimization of the synthetic strategies and deracemization of the lead compound were performed to give highly active compound 10 with low-micromolar potency. Further studies revealed that this compound triggers apoptosis rather than cell cycle arrest as observed with TGZ.
Fichier principal
Vignette du fichier
Dupommier & al preprint.pdf (1.93 Mo) Télécharger le fichier
Corrigendum of Manuscript Boisbrun & al.pdf (422.92 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Loading...

Dates and versions

hal-02421051 , version 1 (20-12-2019)

Identifiers

Cite

Dorian Dupommier, Claire Muller, Corinne Comoy, Sabine Mazerbourg, Andrea Bordessa, et al.. New desulfured troglitazone derivatives: Improved synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2020, 187, pp.111939. ⟨10.1016/j.ejmech.2019.111939⟩. ⟨hal-02421051⟩
184 View
294 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More